Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
16. März 2023 08:05 ET
|
Aeterna Zentaris Inc
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...